ArticleJournal of current ophthalmology2019
The results of aflibercept therapy as a first line treatment of age-related macular degeneration.
Article in Journal of current ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- High-Capacity Mesoporous Silica Nanocarriers of siRNA for Applications in Retinal Delivery.International journal of molecular sciences · 2023Article
- Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.Journal of clinical medicine · 2022Review
- Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration.International journal of retina and vitreous · 2021Article
- Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular DegenerationTurkish journal of ophthalmology · 2021Article
- Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.Pharmacology research & perspectives · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the results of aflibercept treatment in treatment-naive neovascular age-related macular degeneration (AMD) patients and suggest a suitable treatment algorithm for routine clinical practice.
methodThe medical charts of patients treated with intravitreal aflibercept for neovascular AMD were reviewed retrospectively. Best corrected visual acuity, slit-lamp examination, dilated fundus examination, applanation tonometry, and a total number of aflibercept injections were recorded. Aflibercept therapy was applied in an as-needed algorithm after three monthly loading dose. Additionally, optic coherence tomography data, including presence or absence of macular fluid and central macular thickness were recorded.
resultsThirty-eight eyes of 36 patients were included in this study. The mean number of aflibercept injections was 4.86 ± 2.76 (3-18). Mean follow-up time was 12.1 ± 5.7 months (6-26). Thirty-seven eyes (97.3%) achieved maintenance of vision. The mean best corrected visual acuity (logMAR) increased from 0.98 ± 0.56 (0.2-2.4) to 0.57 ± 0.31 (0.1-1.3), (
conclusionsAflibercept therapy appears to be a safe and effective treatment for neovascular AMD. Injections applied in an as-needed algorithm after three monthly loading doses were successful to maintain and improve visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.